“High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)
Department of Health and Human
National Institutes of Health
The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.
This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population.
Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.
This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.
This FOA runs in parallel with another FOA of identical scientific scope, PA-16-426, which utilizes the Exploratory/Developmental Grant (R01) mechanism.
In 2015, NIH and OAR mandated that in the future, AIDS funds can only be used in for research addressing “high” or “medium” priority areas of AIDS research as defined in NOT-OD-15-137“NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding”.
Topics considered “low priority” AIDS in NOT-OD-15-137 are not appropriate for this PAR except basic research in tumors caused by KSHV has, for the moment, been considered as “high priority” AIDS and will be eligible for funding under this PAR. All applications considered for funding will be reviewed by OAR and must be aligned with the priorities in NOT-OD-15-137.
Specific areas of study in the indicated categories may include, but are not limited to, the following examples:
A) Biomarkers, Diagnostics, and Therapeutics:
- Discovery of reliable molecular and immunological diagnostic and prognostic biomarkers and pathogen markers, useful for early detection, progression, or response to treatment of non-AIDS-defining and AIDS-defining malignancies;
- Discovery and development of novel targets and efficacious new therapeutic agents, interventional strategies, or improved delivery systems for the treatment of cancer in people with HIV infection, however clinical trials are not permitted;
- Studies to understand the pharmacokinetics of targeted therapies for AIDS-defining and non-AIDS defining malignancies in the context of highly active antiretroviral therapy and;
- Studies utilizing existing cohorts and tissue banks of human specimens from a wide spectrum of AIDS-defining and non-AIDS defining malignancies to develop biomarker, diagnostic assays, or analyze samples and data acquired from these cohorts is encouraged. Examples of such cohorts and repositories include:
- AIDS and Cancer Specimen Resource (ACSR),
- Women’s Interagency HIV Study (WIHS)),
- Veterans Aging Cohort Study (VACS)
- Multicenter AIDS Cohort Study (MACS).
However, descriptive research and recruitment or retention of cohorts are not appropriate for this FOA.
|Posted Date:||Sep 07, 2016|
|Last Updated Date:||Sep 07, 2016|
|Original Closing Date for Applications:||Sep 07, 2019|
|Current Closing Date for Applications:||Sep 07, 2019|
|Archive Date:||Oct 08, 2019|
|Estimated Total Program Funding:|
|Eligible Applicants:||Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
City or township governments
Native American tribal governments (Federally recognized)
|Additional Information on Eligibility:||Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.|
|Agency Name:||National Institutes of Health|
|Description:||The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.|
|Link to Additional Information:||http://grants.nih.gov/grants/guide/pa-files/PA-16-425.html|
|Grantor Contact Information:||If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV